TREATMENT EFFICIENCY OF ALLERGIC RHINITIS DEPENDS ON PROPER CHOICE OF DRUG

Abstract

Allergic rhinitis is a prevalent, underestimated, and undertreated condition, affecting 25 percent people in Europe [1] and about 30 percent in US [2]. Although allergic rhinitis is not life-threatening disease, but there is no doubt of its socio-economic burden. Direct medical cost per one person with allergic rhinitis is about 4260 euros per year. Allergic rhinitis worsens the quality of life as well. Therefore, a main goal of patient and physician is to reduce the symptoms of allergic rhinitis as soon as possible or completely avoid them by giving adequate the latest research-based treatment. Dymista ® (Azelastine hydrochloride/Fluticasone propionate) effectively reduces the nose (rTNSS) and ocular (rTOSS) symptoms in patients with moderate and severe allergic rhinitis.